Skip to main content
MedPath Trial logoMedPath TrialMedPath Trial Home
Clinical Trials/NCT01239108
NCT01239108WithdrawnPhase 1

A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects With Relapsed/Refractory Leukemias

Astex Pharmaceuticals, Inc.1 site in 1 countryStarted: October 2010Last updated:
Share to TwitterShare to FacebookShare to LinkedInShare to Reddit
Conditions
Drugs

Trial Snapshot

Phase
Phase 1
Status
Withdrawn
Locations
1
Primary Endpoint
The MTD as determined by the incidence of DLTs in the first 4 weeks of each dosing cohort
Study OverviewStudy DesignEligibility CriteriaOutcomesInvestigatorsSitesRecords & IdentifiersSimilar Trials

Study Overview

Brief Summary

Dose escalation study for subjects with Leukemia that has returned or has not responded to standard treatment.

Detailed Description

A Phase 1, Multicenter, Open-label, Dose-escalation Study of SGI-1776, a PIM Kinase Inhibitor, in Subjects with Relapsed/Refractory Leukemias

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Single Group
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • •Men and women with a confirmed diagnosis of leukemia unresponsive to curative therapy
  • •Eastern Cooperative Oncology Group performance status of 0 to 2
  • •Total bilirubin ≤ 1.5 X upper limit of normal (ULN); aspartate transaminase (AST/SGOT) and alanine transaminase (ALT/SGPT) ≤ 3 X ULN; serum creatinine ≤ 2 X ULN
  • •Normal cardiac function with left ventricular ejection fraction ≥ 50% at screening
  • •No clinically significant abnormalities on screening electrocardiogram (ie, QTc interval must be < 470 msec for women and < 450 msec for men and no history of torsades de pointes)
  • •No reproductive potential or willing to use 2 methods of contraception during the study and for 30 days after the last dose
  • •Able to understand the purpose and risks of the study and provide informed consent and authorization to use protected health information

Exclusion Criteria

  • •A life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral SGI-1776, or put the study outcomes at undue risk
  • •Significant cardiovascular disease
  • •Malabsorption syndrome
  • •Symptomatic central nervous system metastases or lesions for which treatment is required
  • •Received prior radiation therapy within 4 weeks of first dose
  • •Grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation
  • •Treatment with any investigational drug within 3 weeks of the first dose
  • •Use of systemic corticosteroids (other than for premedications or intermittent doses such as those used for allergic reactions and control of asthma) or myelosuppressive chemotherapy within 2 weeks of the first dose treatment with nitrosoureas or mitomycin C within 3 weeks of the first dose of SGI 1776
  • •Uncontrolled active systemic infections

Outcomes

Primary Outcomes

The MTD as determined by the incidence of DLTs in the first 4 weeks of each dosing cohort

Time Frame: July 2011

Secondary Outcomes

  • • Frequency, severity, and relationship of adverse events (AEs) and serious adverse events (SAEs) •(1 year)

Investigators

Sponsor Class
Industry
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Completed
Phase 1
BI 836858 Dose Escalation in Patients With Refractory or Relapsed Acute Myeloid Leukemia and in Patients With AML in Complete Remission With High Risk to RelapseLeukemia, Myeloid, Acute
NCT01690624Boehringer Ingelheim30
Recruiting
Phase 1
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)Relapsed Malignant Solid Neoplasm
NCT05865002Aurigene Discovery Technologies Limited50
Completed
Phase 1
BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL)Leukemia, Lymphocytic, Chronic, B-Cell
NCT01296932Boehringer Ingelheim37
Terminated
Phase 1
A Phase 1 Trial of CD33xCD3 BsAb in Pediatric Patients With Relapsed or Refractory Acute Myeloid LeukemiaAML, Childhood
NCT05077423Y-mAbs Therapeutics3
Terminated
Phase 1
Study of the PI3K Inhibitor SL-901 in Patients With Advanced Solid TumorsAdvanced Solid Tumor
NCT05382936Stemline Therapeutics, Inc.20